Sodium/Glucose Cotransporter (SGLT2) Inhibitors- Type 1 and Type 2 Diabetes Cohort Identification

Details

Basic Details

Date Posted

Monday, October 30, 2017

Status

Complete

Medical Product

dipeptidyl peptidase-4 (DPP-4) inhibitor

sodium-glucose cotransporter-2 (SGLT-2) inhibitor

sulfonylurea

Health Outcome(s)

diabetes

type 1 diabetes mellitus

type 2 diabetes mellitus

Description

This report contains the estimated number of new users of Sodium/Glucose Cotransporter (SGLT-2) Inhibitors, Sulfonylureas, and Dipeptidyl peptidase-4 (DPP-4) Inhibitors among all users overall, users with Type I diabetes codes, and users with Type II diabetes codes.

Deliverables (1)

Sentinel Modular Program Report: SGLT2 Inhibitors

Additional Information

Additional Details

FDA Center

CDER

Time Period

April 1, 2013 - September 30, 2015

Analysis Type

Descriptive

Population / Cohort

All individuals

Data Sources

Sentinel Distributed Database (SDD)